Keyword Analysis & Research: ticagrelor vs clopidogrel

drugs.com

https://www.drugs.com/medical-answers/ticagrelor-clopidogrel-3541945/

DA: 74 PA: 69 MOZ Rank: 94

tsoc.org.tw

https://www.tsoc.org.tw/upload/files/2020%20Focused%20Update%20of%20STEMI.pdf

DA: 72 PA: 55 MOZ Rank: 72

nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa0904327

WebSep 10, 2009 · Ticagrelor, a reversible and direct-acting oral antagonist of the adenosine diphosphate receptor P2Y12, provides faster, … Author: Lars Wallentin, Richard C. Becker, Andrzej Budaj, Christopher P. Cannon, Håkan Emanuelsson, Claes He... Publish Year: 2009

Author: Lars Wallentin, Richard C. Becker, Andrzej Budaj, Christopher P. Cannon, Håkan Emanuelsson, Claes He...

Publish Year: 2009

DA: 36 PA: 24 MOZ Rank: 35

drugs.com

https://www.drugs.com/medical-answers/ticagrelor-clopidogrel-3541945/

WebMay 18, 2023 · Ticagrelor is preferred over clopidogrel for dual antiplatelet therapy in ACS or STEMI patients, according to current guidelines. Ticagrelor is more effective, faster, … Occupation: Senior Editorial Pharmacist

Occupation: Senior Editorial Pharmacist

DA: 92 PA: 41 MOZ Rank: 81

verywellhealth.com

https://www.verywellhealth.com/brilinta-ticagrelor-vs-plavix-clopidogrel-8404445

WebPublished on December 05, 2023. Medically reviewed by Femi Aremu, PharmD. Print. Table of Contents. Uses. Which Is More Effective? Safety Warnings and Risks. Side Effects. …

DA: 47 PA: 21 MOZ Rank: 27

mayoclinicproceedings.org

https://www.mayoclinicproceedings.org/article/S0025-6196(23)00060-5/fulltext

WebTicagrelor use, compared with clopidogrel, was associated with a significantly lower risk of ischemic events (2.60% vs 3.74%; HR, 0.69; 95% CI, 0.51 to 0.94; P=.02). There was a significant reduction in the …

DA: 5 PA: 85 MOZ Rank: 83

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322751/

WebFeb 10, 2021 · Ticagrelor, a reversible and direct-acting oral antagonist of the adenosine diphosphate receptor P2Y12, provides faster and more consistent platelet inhibition than …

DA: 47 PA: 18 MOZ Rank: 83

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785207/

WebJan 10, 2022 · Several studies suggest that ticagrelor has superior efficacy over clopidogrel in reducing the risk of major adverse cardiovascular events in patients with acute …

DA: 32 PA: 65 MOZ Rank: 29

ajconline.org

https://www.ajconline.org/article/S0002-9149(23)01198-0/fulltext

WebNov 17, 2023 · However, whether a potent P2Y 12 inhibitor (ticagrelor) or a less potent one (clopidogrel) is more appropriate in patients with acute coronary syndrome (ACS) in …

DA: 10 PA: 31 MOZ Rank: 77

jamanetwork.com

https://jamanetwork.com/journals/jama/fullarticle/2776872

WebBecause clopidogrel has limited antiplatelet effect to prevent atherothrombotic event occurrence in patients with AMI, potent P2Y12 inhibitors may have more clinical benefit …

DA: 32 PA: 38 MOZ Rank: 76

ahajournals.org

https://www.ahajournals.org/doi/10.1161/JAHA.119.012530

WebSep 5, 2019 · The primary efficacy outcome occurred in 32.4% of patients treated with clopidogrel versus 25.5% treated with ticagrelor ( P =0.015), with the 1‐year mortality …

DA: 64 PA: 2 MOZ Rank: 4

ajconline.org

https://www.ajconline.org/article/S0002-9149(23)01255-9/fulltext

WebNov 22, 2023 · Ticagrelor is a reversible inhibitor that produces more rapid, consistent, and stronger inhibition of platelet aggregation than clopidogrel. Clopidogrel is a prodrug …

DA: 17 PA: 29 MOZ Rank: 84